On June 18, Boston Scientific fell 3.24% in regular trading, trading at $45.325/share, with turnover of $451 million. The stock hit a fresh 52-week low as selling pressure intensified.

On the news front, Piper Sandler recently slashed its price target on Boston Scientific from $90 to $65, a reduction of nearly 28%, while maintaining a buy rating. According to analyst consensus, the stock carries an average buy rating with a mean target of $76.57. The significant target price cut has amplified bearish sentiment in the market despite the maintained buy recommendation.

At the industry level, the Health Care Equipment sector faced broad-based selling pressure, with sector-wide declines magnifying individual stock losses. Among peer companies, Abbott fell 2.41%, Intuitive Surgical dropped 2.89%, Stryker declined 3.27%, and Medtronic fell 3.91%. The company is scheduled to report next quarter earnings on July 29 pre-market, and markets may be pricing in uncertainty ahead of the release.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)